Chimerix Announces TEMBEXA Procurement Agreement for Approximately $25.3 Million with Public Health Agency of Canada
June 24, 2022 10:06 ET
|
Chimerix, Inc.
DURHAM, N.C., June 24, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of...
Chimerix Announces $9.3 Million International TEMBEXA Procurement Agreement
June 23, 2022 09:15 ET
|
Chimerix, Inc.
DURHAM, N.C., June 23, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of...
Chimerix to Present at Jefferies Global Healthcare Conference
June 01, 2022 16:30 ET
|
Chimerix, Inc.
DURHAM, N.C., June 01, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of...
Chimerix to Present at H.C. Wainwright Global Investment Conference
May 17, 2022 16:15 ET
|
Chimerix, Inc.
DURHAM, N.C., May 17, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients...
Chimerix Reports First Quarter 2022 Financial Results and Provides Operational Update
May 16, 2022 07:00 ET
|
Chimerix, Inc.
– Receiving up to $337.5 Million plus Royalties for Sale of Worldwide Rights of TEMBEXA to Emergent BioSolutions – – Initiation of Phase 3 Randomized Study of ONC201 in H3 K27M Mutant Glioma Expected...
Chimerix Announces Sale of TEMBEXA to Emergent BioSolutions for up to $337.5 Million plus Royalties
May 16, 2022 06:30 ET
|
Chimerix, Inc.
– $225 Million in Upfront Proceeds Secures Substantial Capital to Fund Operations and Allows for Participation in Future Economics – – Transaction Allows for Focus on Development Pipeline – –...
Chimerix to Participate in Maxim Group Panel Discussion
May 12, 2022 16:15 ET
|
Chimerix, Inc.
DURHAM, N.C., May 12, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients...
Chimerix to Report First Quarter 2022 Financial Results and Provide an Operational Update on May 16, 2022
May 09, 2022 07:00 ET
|
Chimerix, Inc.
DURHAM, N.C., May 09, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients...
Chimerix to Present at Maxim Group 2022 Virtual Growth Conference
March 21, 2022 07:00 ET
|
Chimerix, Inc.
DURHAM, N.C., March 21, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients...
Chimerix Reports Fourth Quarter and Year End 2021 Financial Results and Provides Operational Update
March 01, 2022 07:00 ET
|
Chimerix, Inc.
– TEMBEXA RFP Response Submitted and Under Review with BARDA – – Pre-Clinical CMX521 Data Accepted for Late Breaking Oral Presentation at International Conference on Antiviral Research – – ONC201...